Drug profile · INN
tenofovir alafenamide fumarate
VEMLIDY
tenofovir alafenamide fumarate (VEMLIDY) is a human immunodeficiency virus type 1 reverse transcriptase inhibitor. Route of administration: oral. Current US regulatory status: approved.
Drug details — tenofovir alafenamide fumarate
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 0
- Programs
- 22
- Data quality
- 0.84
Quick answer
tenofovir alafenamide fumarate (VEMLIDY) is a human immunodeficiency virus type 1 reverse transcriptase inhibitor. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Human immunodeficiency virus type 1 reverse transcriptase inhibitor
Primary target: Human immunodeficiency virus type 1 reverse transcriptase
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| PMDA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is tenofovir alafenamide fumarate?
tenofovir alafenamide fumarate (VEMLIDY) is a human immunodeficiency virus type 1 reverse transcriptase inhibitor. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for tenofovir alafenamide fumarate?
VEMLIDY is a marketed brand name for tenofovir alafenamide fumarate. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of tenofovir alafenamide fumarate?
tenofovir alafenamide fumarate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.